export const pharmacologyData = {
  name: "Pharmacology",
  subtopics: {
    "general-pharmacology": {
      name: "General Pharmacology",
      subtopics: {
        essay: {
          name: "Essay",
          questions: [
            "Biotransformation ** (Aug 14;Feb 10) (Pg.No: 28)\nDiscuss:\n- Biotransformation Reactions, Phase I and Phase II reaction with suitable examples\n- Importance of Enzyme Induction and Enzyme Inhibition\n- Microsomal Enzyme Induction and Inhibition with examples\n\nProbable Case:\nA 35 year old woman taking combined oral contraceptive pills was diagnosed with tuberculosis and put on isoniazid, rifampicin, pyrazinamide, and ethambutol combination therapy for 2 months followed by isoniazid and rifampicin thrice weekly for 4 months. In the 3rd month of treatment, she failed to have withdrawal bleeding during the gap period of contraceptive cycle. One week later her urinary pregnancy test was found to be positive.",
            "Factors Modifying Drug Action ** (Aug 15;Aug 10) (Pg.No: 73)\nDiscuss:\n- Definition Drug and Dose\n- Various Factors Modifying a Drug's Actions\n- Note about Pharmacogenetics",
            "Routes of Drug Administration (Apr 01) (Pg.No: 9)\nExplain:\n- Each Route of Administration\n- Examples\n- Advantages and Disadvantages"
          ]
        },
        "short-note": {
          name: "Short Note",
          questions: [
            "Biological Half Life (or) Plasma Half Life ****** (Jul 23;Aug 18;Feb 17;Aug 05;Mar 02;Nov 95) (Pg.No: 39)\n- Drugs with short half-life\n- Drugs with long and very short half life",
            "Drug Tolerance (Tachyphylaxis) ****** (Feb 23;Feb 22;Aug 17;Feb 09;Mar 02;Apr 97) (Pg.No: 80)",
            "Pharmacogenetics ****** (Feb 23;Sep 21;Aug 17;Feb 09;Feb 08;Apr 01) (Pg.No: 75)",
            "Pharmacovigilance ****** (Aug 22;Mar 22;Sep 21;Feb 18;Feb 16;Aug 13) (Pg.No: 93)",
            "Newer Drug Delivery System ***** (Feb 23;Feb 13;Feb 11;Feb 08;Nov 94) (Pg.No: 42)",
            "Bioavailability **** (Feb 20;Aug 09;Aug 04;Apr 01) (Pg.No: 22)",
            "First Pass Metabolism (Pre-Systemic Elimination) **** (Aug 16;Feb 07;Oct 98;Jan 93) (Pg.No: 34)",
            "Drug Antagonism *** (Feb 12;Feb 05;Nov 01) (Pg.No: 67)",
            "Sublingual Route of Drug Administration *** (Aug 11;Aug 08;Oct 97) (Pg.No: 12)",
            "Teratogenicity *** (Aug 22;Feb 19;Nov 01) (Pg.No: 99)",
            "Biotransformation ** (Aug 08;Apr 99) (Pg.No: 28)",
            "Microsomal Enzyme Inducers ** (Feb 23;Feb 12) (Pg.No: 33)",
            "Phase 2 Biotransformation Reactions with Suitable Examples ** (Mar 22;Feb 20) (Pg.No: 31)",
            "Phase III Clinical Trial ** (Feb 22;Feb 19) (Pg.No: 91)",
            "Post Marketing Surveillance During Newer Drug Development (Phase IV Clinical Trial) ** (Feb 17;Nov 95) (Pg.No: 91)",
            "Prolongation Of Drug Action ** (Jul 23;Apr 96) (Pg.No: 42)",
            "Protein Binding of Drugs ** (Sep 21;Oct 03) (Pg.No: 25)\n- Clinical significance with Examples",
            "Therapeutic Index ** (Aug 07;Oct 96) (Pg.No: 65)",
            "Transdermal Application Of Drugs ** (Feb 22;Oct 00) (Pg.No: 12)",
            "Blood Brain Barrier (Aug 11) (Pg.No: 24)",
            "Causality Assessment (Aug 22) (Pg.No: 93)",
            "Drug Receptor (Oct 00) (Pg.No: 48)",
            "Drug Responses in Elderly (Aug 12) (Pg.No: 74)",
            "Drug Synergism (Feb 16) (Pg.No: 66)",
            "Drugs in Anaphylactic Shock (Pg.No: 97)",
            "Essential Drugs (Feb 12) (Pg.No: 6)",
            "Fixed Dose Ratio Combination (Feb 13) (Pg.No: 72)",
            "Iatrogenicity (Oct 00) (Pg.No: 101)",
            "Intracellular Receptors (Nov 20) (Pg.No: 60)",
            "Local Routes Of Drug Administration (Feb 10) (Pg.No: 10)",
            "Orphan Drugs (Aug 18) (Pg.No: 7)",
            "Parenteral Route of Drug Administration (Aug 19) (Pg.No: 13)",
            "Pharmacokinetics (Pg.No: 15)",
            "Phase 1 Biotransformation Reaction with Examples (Aug 06) (Pg.No: 29)",
            "Physical Antagonism (Nov 20) (Pg.No: 67)",
            "Prodrug (Aug 04) (Pg.No: 28)",
            "Receptor Antagonism (Aug 11) (Pg.No: 68)",
            "Rectal Route of Administration (Dec 23) (Pg.No: 12)",
            "Specialized Active Transport Mechanism Across Biological Membrane (Aug 13) (Pg.No: 18)",
            "Zero Order Pharmacokinetics (Aug 19) (Pg.No: 38)"
          ]
        }
      }
    },
    "respiratory-system": {
      name: "Respiratory System",
      subtopics: {
        essay: {
          name: "Essay",
          questions: [
            "Drugs used in Bronchial Asthma ** (Aug 11;Feb 07) (Pg.No: 241)\n- Mechanism of Action, Uses, Adverse Effects, Classification",
            "Role of Sympathomimetics in Bronchial Asthma (Aug 12) (Pg.No: 222)"
          ]
        },
        "short-note": {
          name: "Short Note",
          questions: [
            "Steroids Used in Bronchial Asthma ******* (Aug 20;Aug 18;Aug 17;Feb 17;Feb 12;Aug 09;Aug 04) (Pg.No: 249)\n- Role, Adverse effects",
            "Antitussives ***** (Feb 23;Feb 21;Aug 18;Aug 17;Aug 11) (Pg.No: 239)\n- Mechanism of Action, Uses, Adverse Effects, Examples",
            "Mast Cell Stabilisers ***** (Aug 18;Feb 16;Feb 11;Feb 10;Apr 00) (Pg.No: 249)",
            "Status Asthmaticus ***** (Aug 19;Feb 14;Aug 05;Oct 03;Oct 00) (Pg.No: 253)\n- Drugs Used, Management",
            "Nasal decongestants **** (Jul 23;Feb 16;Feb 07;Apr 00) (Pg.No: 238)\n- Classification, Mechanism of Action, Uses, Adverse Effects",
            "Mucolytics (or) Mucokinetics *** (Feb 19;Aug 13;Feb 10) (Pg.No: 238)",
            "Cromolyn Sodium (or) Sodium Cromoglycate ** (Feb 18;Mar 02) (Pg.No: 249)",
            "Leukotriene Antagonists in Bronchial Asthma ** (Aug 13;Aug 10) (Pg.No: 248)\n- Mechanism of Action, Uses, Adverse Effects, Indications",
            "Role of Glucocorticoids in Bronchial Asthma ** (Feb 15;Apr 98) (Pg.No: 249)",
            "Salbutamol ** (Aug 15;Oct 97) (Pg.No: 242)",
            "Anti-Asthmatic Drugs (Feb 14) (Pg.No: 241)",
            "Bromhexine (Feb 16) (Pg.No: 238)",
            "Bronchodilators (Aug 07) (Pg.No: 242)\n- Classification: Sympathomimmetics, Methyl xanthines, Anticholinergics, Mechanism of action, Uses, Adverse Effects",
            "Centrally Acting Cough Suppressants (Aug 12) (Pg.No: 239)\n- Uses",
            "Centrally Acting Cough Syrup (Nov 01) (Pg.No: 239)\n- Classification, Mechanism of action, Uses, Adverse Effects",
            "Dextromethorphan (Nov 01) (Pg.No: 239)",
            "Expectorants (Feb 05) (Pg.No: 238)",
            "Ipratropium bromide (Aug 14) (Pg.No: 248)",
            "Methyl Xanthines in Bronchial Asthma (Nov 01) (Pg.No: 243)",
            "Montelukast (Aug 11) (Pg.No: 248)\n- Mechanism of Action, Uses",
            "Theophylline (Feb 20) (Pg.No: 246)",
            "Zileuton (Aug 05) (Pg.No: 249)"
          ]
        }
      }
    },
    "autacoids": {
      name: "Autacoids",
      subtopics: {
        essay: {
          name: "Essay",
          questions: [
            "Salicylates ***** (Feb 23;Feb 15;Aug 08;Feb 08;Nov 01) (Pg.No: 212;TV4- Pg.No: 241)\n- Mechanism of Action, Pharmacological Action, Therapeutic Uses, Adverse Effects, Classification of NSAIDS"
          ]
        },
        "short-note": {
          name: "Short Note",
          questions: [
            "Drug therapy of Chronic Gout ******* (Jul 23;Feb 23;Feb 22;Feb 15;Aug 11;Aug 10;Feb 08) (Pg.No: 232;TV4-Pg.No: 250)\n- Uricosuric Agents\n- Probenecid",
            "Second Generation Antihistamines ******* (Feb 20;Aug 19;Aug 14;Aug 13;Aug 08;Aug 05;Aug 04) (Pg.No: 181;TV4-Pg.No: 232)\n- Non Sedative H1 Blockers\n- Ebastine\n- Azelastine\n- Rupatadine",
            "Therapeutic Uses of Prostaglandins ******* (Aug 22;Feb 17;Feb 14;Aug 11;Feb 11;Aug 10;Aug 08) (Pg.No: 205;TV4-Pg.No: 238)",
            "Selective Cox-2 Inhibitors ****** (Feb 18;Aug 14;Aug 11;Feb 10;Aug 09;Aug 08) (Pg.No: 221;TV4-Pg.No: 247)",
            "Aspirin ***** (Jul 23;Feb 19;Feb 16;Aug 13;Feb 11) (Pg.No: 212;TV4-Pg.No: 241)\n- Contraindications\n- Effects on Acid Base and Electrolyte Balance\n- Dose Dependant Actions\n- Uses",
            "Drugs used in Prophylaxis of Migraine ***** (Mar 22;Aug 17;Aug 11;Feb 09;Apr 00) (Pg.No: 194;TV4-Pg.No: 237)",
            "Pharmacotherapy of Migraine ***** (Aug 22;Feb 19;Feb 15;Aug 12;Aug 10) (Pg.No: 192;TV4-Pg.No: 235)\n- Selective Serotonin (5-HT) 1B, 1D agonist\n- Sumatriptan",
            "Acute Gout *** (Feb 23;Aug 14;Feb 12) (Pg.No: 231;TV4-Pg.No: 249)",
            "Serotonin (5-HT) Antagonist *** (Aug 13;Feb 07;Feb 05) (Pg.No: 189;TV4- Pg.No: 234)\n- Cyproheptadine",
            "Disease Modifying Anti-Rheumatic Drugs (DMARDs) ** (Aug 22;Feb 11) (Pg.No: 227;TV4-Pg.No: 252)",
            "Nimesulide ** (Aug 15;Aug 12) (Pg.No: 220;TV4-Pg.No: 245)",
            "Acute Paracetamol Poisoning (Aug 14) (Pg.No: 223;TV4-Pg.No: 248)",
            "Difference between 1st and 2nd Generation Antihistamines (Feb 20) (Pg.No: 179;TV4-Pg.No: 231)",
            "First Generation Antihistamines (Aug 13) (Pg.No: 174;TV4-Pg.No: 231)",
            "Ketorolac (Aug 15) (Pg.No: 219;TV4-Pg.No: 246)",
            "Role of Biologics in Rheumatoid Arthritis (Nov 20) (Pg.No: 230;TV4-Pg.No: 254)",
            "Therapeutic Uses of H1 Antihistamines (Feb 11) (Pg.No: 178;TV4-Pg.No: 231)"
          ]
        }
      }
    }
  }
};
